Linked Life Data

7882547

Source:http://linkedlifedata.com/resource/pubmed/id/7882547

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1995-4-13
pubmed:abstractText
Familial adenomatous polyposis (FAP) is characterized by multiple adenomatous colorectal polyps, some of which progress to adenocarcinoma in the absence of surgery. Colectomy with ileorectal anastomosis still remains much in use, although strict surveillance of the rectal stump is necessary to prevent rectal cancer. After 1983, sulindac has been used to control rectal polyps in about 90 FAP patients, at doses of 150-400 mg/day. The treatment was well tolerated, and regression of the polyps was frequently observed. However, recurrence of polyps was sometimes observed, and the onset of rectal cancer during sulindac therapy was also reported. A review of the literature and the personal experience of the authors are here presented, discussing the pharmacological profile and possible mechanisms of action of sulindac.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0257-2753
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
259-64
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Sulindac therapy of colorectal polyps in familial adenomatous polyposis.
pubmed:affiliation
Dipartimenti di Fisiopatologia Clinica, Università di Firenze, Italia.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't